29th November 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

Mankind pharma acquires major part of stake in Upakarma Pharma

On Monday, Mankind Pharma announced the acquisition of majority stakes in Uparkarma Pharma for an undisclosed amount. The investment will allow the Ayurveda and herbal-based company to strengthen their product profile and offerings.

Akums Pharma expects to reach ₹10,000 Crore turnover in next five years

Akums Pharma, a leading contract manufacturing drug firm is planning to expand its business globally and increase its product range to hike its revenue to ₹10,000 Crore by 2028, as stated by the firm’s Managing Director.

Lupin's Brazil-based subsidiary MedQuimica acquires 9 brands from Bausch Health

Lupin Limited announced on Monday that their wholly owned subsidiary in Brazil, MedQuímica, has signed an agreement to acquire all rights to nine medicines from BL Indústria Ótica Ltda., a subsidiary of Bausch Health Companies Inc.

AstraZeneca receives USFDA approval for Dapagliflozin tablets

The drug major declared that they have received permission for import and marketing in Form CT-20 (subsequent new drug approval) from the CDSCO (Central Drugs Standard Control Organisation) for Dapagliflozin tablets of 10 mg.

C4XD signs pact with AstraZeneca worth up to $402 million for NRF2 activator programme

Leading drug discovery company C4X Discovery Holdings plc. has signed an exclusive worldwide licensing agreement with AstraZeneca worth almost $402 million, for its NRF2 Activator program indicated oral therapy for the treatment of inflammatory and respiratory diseases.

Maharashtra govt to set up bulk drug park in Raigad district

The Maharashtra government is planning to set up a bulk drug park in Raigad district to cut the cost of manufacturing bulk drugs by creating state-of-art infrastructure facilities supported by the central government.

FDA Accepts Roche & Sarepta's BLA for DMD Gene Therapy

The FDA has recently accepted Roche and Sarepta’s BLA (Biologic License Application) for the accelerated approval of SRP-9001 (delandistrogene moxeparvovec), an investigational gene therapy candidate indicated for DMD (Duchenne Muscular Dystrophy).

PharmaState.academy offers easy access to training & up-skilling programs created by experts from Pharma Industry.

Update profile

Please update your profile to keep using the website

Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?